Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Sykora

Anesthesiology Philadelphia, PA Doctor of Osteopathy

NPI 1366795080 CMS profile 1962988

111 S 11Th St, Philadelphia, PA 19107

Open in the dashboard

General payments

$5,254

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Sykora of Philadelphia, PA is reported in the CMS Open Payments database as having received $5,254 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $308 3
2024 General $930 10
2023 General $522 10
2022 General $2,716 30
2021 General $54 3
2020 General $147 10
2019 General $576 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Sykora
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Peter Sykora were reported at $308. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Peter Sykora Anesthesiology median Middle half National median
2019 $576 $72 $23–$151 $163
2020 $147 $36 $17–$120 $114
2021 $54 $49 $21–$135 $132
2022 $2,716 $52 $22–$144 $149
2023 $522 $53 $23–$143 $160
2024 $930 $55 $25–$150 $164
2025 $308 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,741 21 payments
  2. Medtronic, Inc. $1,116 10 payments
  3. Abbott Laboratories $1,110 34 payments
  4. Stryker Corporation $883 8 payments
  5. Curonix LLC $240 2 payments
  6. Avanos Medical $131 1 payment
  7. Merck Sharp & Dohme Corporation $23 1 payment
  8. Allergan Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,386 63 payments
  2. Travel and Lodging $1,947 13 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $892 1 payment
  4. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. Omnia $1,272 13 payments
  2. INTELLIS ADAPTIVESTIM $1,038 6 payments
  3. AUGMENT INJECTABLE $717 6 payments
  4. Senza $361 7 payments
  5. Proclaim Family of SCS IPGs $274 4 payments
  6. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $240 2 payments
  7. ETERNA $203 3 payments
  8. PROCLAIM $190 4 payments
  9. MILD DEVICE KIT $167 2 payments
  10. ON-Q* PUMP AND ACCESSORIES $131 1 payment
  11. Other $695 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,893

Median for Pain Management: 951

Drug cost

$105,931

Median for Pain Management: $26,034

Branded share of claims

34.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Tapentadol Hcl Brand 20 $24,134
Xtampza Er Oxycodone Myristate Brand 32 $23,469
Belbuca Buprenorphine Hcl Brand 18 $16,267
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 262 $7,961
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 236 $7,865
Pregabalin Generic 190 $5,152
Gabapentin Generic 319 $4,348
Oxycodone Hcl Generic 195 $3,762
Lidocaine Generic 16 $2,616
Buprenorphine Generic 13 $1,989

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$87,654

Of which drugs: $822

Medicare patients

274

Average age 73

Services billed

1,160

158 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Depression 32%
COPD 27%
Ischemic heart disease 23%
Osteoporosis 23%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 40 179 $140

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record